Frontier AI companies as biotech acquirers

- Friends! Frontier AI firms are acquiring early-stage biology platforms, a shift from traditional pharma exits. This isn't just a merger; it's a structural realignment of the med-tech supply chain. For founders and investors, the valuation metrics are changing—data integrity now outweighs pure IP. I treated cats. Same thing, only more honest. The "meat wallet" of the patient remains central, but the diagnostic dance is being rewritten by algorithms. We must watch for friction in these PoD seals between silicon and synapse. No panic, just a careful audit of who holds the keys to the trial data. Truth smugglers beware: the market is getting smarter, but so is the risk.